Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

917 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Vermeire S, Danese S, Zhou W, Ilo D, Klaff J, Levy G, Yao X, Chen S, Sanchez Gonzalez Y, Hébuterne X, Lindsay JO, Higgins PDR, Cao Q, Nakase H, Colombel JF, Loftus EV Jr, Panaccione R. Vermeire S, et al. Among authors: nakase h. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9. Lancet Gastroenterol Hepatol. 2023. PMID: 37683686
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, D'Haens G, Panaccione R, Reinisch W, Louis E, Chen M, Nakase H, Begun J, Boland BS, Phillips C, Mohamed MF, Liu J, Geng Z, Feng T, Dubcenco E, Colombel JF. Loftus EV Jr, et al. Among authors: nakase h. N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728. N Engl J Med. 2023. PMID: 37224198 Free article. Clinical Trial.
Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies.
Gao X, Fujii T, Ye BD, Chou JW, Sugimoto K, Cao Q, Kligys K, Murakoshi K, Teng D, Zhang Y, Nakase H. Gao X, et al. Among authors: nakase h. J Gastroenterol Hepatol. 2024 Jan;39(1):55-65. doi: 10.1111/jgh.16358. Epub 2023 Oct 3. J Gastroenterol Hepatol. 2024. PMID: 37788676 Clinical Trial.
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Panaccione R, Danese S, Zhou W, Klaff J, Ilo D, Yao X, Levy G, Higgins PDR, Loftus EV Jr, Chen S, Gonzalez YS, Leonard C, Hébuterne X, Lindsay JO, Cao Q, Nakase H, Colombel JF, Vermeire S. Panaccione R, et al. Among authors: nakase h. Aliment Pharmacol Ther. 2024 Feb;59(3):393-408. doi: 10.1111/apt.17816. Epub 2023 Nov 27. Aliment Pharmacol Ther. 2024. PMID: 38010661
Serum amyloid A1 recruits neutrophils to the invasive front of T1 colorectal cancers.
Yoshido A, Sudo G, Takasawa A, Aoki H, Kitajima H, Yamamoto E, Niinuma T, Harada T, Kubo T, Sasaki H, Ishiguro K, Yorozu A, Kai M, Katanuma A, Yamano HO, Osanai M, Nakase H, Suzuki H. Yoshido A, et al. Among authors: nakase h. J Gastroenterol Hepatol. 2023 Feb;38(2):301-310. doi: 10.1111/jgh.16055. Epub 2022 Nov 20. J Gastroenterol Hepatol. 2023. PMID: 36345658
An older patient with active ulcerative colitis and coronavirus disease 2019 (COVID-19) pneumonia successfully treated with the combination of anti-TNFα therapy and azathioprine.
Yamakawa T, Ishigami K, Ohwada S, Kazama T, Hirayama D, Yoshii S, Yamano HO, Nakase H. Yamakawa T, et al. Among authors: nakase h. Clin J Gastroenterol. 2023 Apr;16(2):187-192. doi: 10.1007/s12328-022-01737-y. Epub 2022 Nov 23. Clin J Gastroenterol. 2023. PMID: 36417106 Free PMC article.
Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study.
Kubota K, Kamisawa T, Nakazawa T, Tanaka A, Naitoh I, Kurita Y, Takikawa H, Unno M, Kawa S, Masamune A, Nakamura S, Okazaki K; Collaborators. Kubota K, et al. J Gastroenterol Hepatol. 2023 Apr;38(4):556-564. doi: 10.1111/jgh.16066. Epub 2023 Jan 10. J Gastroenterol Hepatol. 2023. PMID: 36403136
Immune-related colitis and pancreatitis treated with infliximab.
Ohwada S, Ishigami K, Yokoyama Y, Kazama T, Masaki Y, Takahashi M, Yoshii S, Yamano HO, Chiba H, Nakase H. Ohwada S, et al. Among authors: nakase h. Clin J Gastroenterol. 2023 Feb;16(1):73-80. doi: 10.1007/s12328-022-01731-4. Epub 2022 Nov 21. Clin J Gastroenterol. 2023. PMID: 36414888
Effectiveness and Factors Associated with Response to Golimumab in Japanese Patients with Ulcerative Colitis in Real Clinical Practice: The Phoenix Study.
Hirayama D, Motoya S, Ashida T, Ando K, Fujiya M, Ito T, Furukawa S, Maemoto A, Katsurada T, Hinotsu S, Sato N, Mizuno N, Ikawa Y, Nakase H. Hirayama D, et al. Among authors: nakase h. Inflamm Intest Dis. 2023 Aug 31;8(3):115-127. doi: 10.1159/000533871. eCollection 2023 Dec. Inflamm Intest Dis. 2023. PMID: 38098492 Free PMC article.
917 results